PDX model details
| PDX ID |
387.38A Cx |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Castrate |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
12 (4*) |
| Average PDX Generation Time (days +/- SEM) |
201 ± 35 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
387.38A Cx |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
Y |
| ERG |
Y |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 387.38A Cx |
MLH1 |
0.665 |
3.171 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
CTNNB1 |
0.829 |
3.552 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
MYC |
1.147 |
4.430 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
AKT1 |
0.647 |
3.133 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
GNAS |
0.693 |
3.234 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
KDM6A |
1.449 |
2.731 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
AR |
4.041 |
16.462 |
Gain-High
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
ZFHX3 |
-1.546 |
0.685 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
TP53 |
-1.697 |
0.617 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 387.38A Cx |
AXIN2 |
-1.643 |
0.640 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
387.38A |
| Sample Site |
Para-tracheal lymph node |
| Sample source |
Autopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, cabazitaxel, enzalutamide, lutetium PSMA, pembrolizumab |
| |
|
Patient Information
| Patient Number |
387 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 387.38A Cx |
TP53 |
93 |
1.0 |
Missense variant |
'6/11 |
. |
24.8 |
Conflicting interpretations of pathogenicity
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 387.38A Cx |
CRLF2 |
271 |
1.0 |
Missense variant |
'6/6 |
. |
9.837 |
Not provided
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 387.38A Cx |
KMT2C |
404 |
0.71 |
Missense variant |
'43/59 |
4.48E-05 |
23.2 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 387.38A Cx |
NOTCH3 |
413 |
0.51 |
Missense variant |
'25/33 |
2.22E-05 |
16.93 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 387.38A Cx |
UGT1A10 |
403 |
0.32 |
Missense variant |
'1/5 |
0.0001666 |
22.8 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 387.38A Cx |
DPCR1 |
542 |
0.29 |
Stop gained |
'2/3 |
. |
24.6 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 387.38A Cx |
DPCR1 |
542 |
0.29 |
Stop gained |
'2/3 |
. |
24.6 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table